Comparative Analysis of Cardiovascular Disorders in Patients with Chronic Myeloid Leukemia on Tyrosine Kinase Inhibitor Therapy

Autor: E. I. Emelina, OYu Vinogradova, Igor G. Nikitin, G. E. Gendlin, Immunology, Samory Mashela str., Moscow, Russian Federation, Anastasiya Bykova, IE Lazarev, EYu Chelysheva, EG Arshanskaya, Galina Gusarova, L M Makeeva, Anna G. Turkina

Publikováno v: Kliničeskaâ onkogematologiâ, Vol 13, Iss 1, Pp 104-111 (2019)

Aim. To analyze adverse cardiovascular events in chronic myeloid leukemia (CML) patients who received various tyrosine kinase inhibitors (TKI). Materials & Methods. The trial included 97 CML patients with nilotinib, dasatinib or imatinib indications.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f7fc3302de67febb6b4b1068d2217458
https://doi.org/10.21320/2500-2139-2020-13-1-104-111

Thrombopoietin Receptor Agonists in the Treatment of Chronic Resistant Primary Immune Thrombocytopenia: Efficacy and Safety Data in Real Clinical Practice

Autor: Vadim V. Ptushkin, N.E. Tkachenko, EG Arshanskaya, MM Pankrashkina, M V Chernikov, O.Yu. Vinogradova

Publikováno v: Терапевтический архив, Vol 90, Iss 7, Pp 70-76 (2018)

Objective: To analyze the long-term efficacy and safety of ATR in adult patients with primary resistant ITP in real-world clinical practice. Materials and methods.The article contains long-term results analysis of ATR application under real clinical

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::401324dcf61db0f836e80e71cc74ed68
https://pubmed.ncbi.nlm.nih.gov/30701925

Thrombopoietin Receptor Agonists in the Treatment of Chronic Resistant Primary Immune Thrombocytopenia: Efficacy and Safety Data in Real Clinical Practice.

Autor: Ptushkin VV; The City Clinical Hospital named after S.P. Botkin Moscow Department of Health, Moscow, Russia.; National Medical Research Center of Children's Hematology, Oncology and Immunology named after Dmitry Rogachev of the Russian Federation Ministry of Health, Moscow, Russia.; Russian National Medical Research University named after N.I. Pirogov, Russian Federation Ministry of Health. Department of Hematology, Oncology and Radiation Therapy, Moscow, Russia., Vinogradova OY; The City Clinical Hospital named after S.P. Botkin Moscow Department of Health, Moscow, Russia.; National Medical Research Center of Children's Hematology, Oncology and Immunology named after Dmitry Rogachev of the Russian Federation Ministry of Health, Moscow, Russia.; Russian National Medical Research University named after N.I. Pirogov, Russian Federation Ministry of Health. Department of Hematology, Oncology and Radiation Therapy, Moscow, Russia., Pankrashkina MM; The City Clinical Hospital named after S.P. Botkin Moscow Department of Health, Moscow, Russia.; National Medical Research Center of Children's Hematology, Oncology and Immunology named after Dmitry Rogachev of the Russian Federation Ministry of Health, Moscow, Russia.; Healthcare and Medical Management Research Institute of the Moscow City Health Department, Moscow, Russia., Chernikov MV; The City Clinical Hospital named after S.P. Botkin Moscow Department of Health, Moscow, Russia.; Healthcare and Medical Management Research Institute of the Moscow City Health Department, Moscow, Russia., Arshanskaya EG; The City Clinical Hospital named after S.P. Botkin Moscow Department of Health, Moscow, Russia.; National Medical Research Center of Children's Hematology, Oncology and Immunology named after Dmitry Rogachev of the Russian Federation Ministry of Health, Moscow, Russia., Tkachenko NE; National Medical Research Center of Children's Hematology, Oncology and Immunology named after Dmitry Rogachev of the Russian Federation Ministry of Health, Moscow, Russia.

Publikováno v: Terapevticheskii arkhiv [Ter Arkh] 2018 Aug 17; Vol. 90 (7), pp. 70-76.